BioSpace News Archive

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), today reported financial results for the third quarter and nine months ended September 30, 2021, and highlighted recent corporate progress.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2021.

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2021, together with other business updates.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

Sight Sciences, Inc. announced that the Food and Drug Administration has granted an Investigational Device Exemption authorizing the Company to conduct a clinical study to assess the safety and effectiveness of a new, higher volume, investigational OMNI® device to perform canal viscodilation alone to lower intraocular pressure in adults with primary open-angle glaucoma.

Progenity, Inc., an innovative biotechnology company, provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Opiant Pharmaceuticals, Inc., a company advancing medicines to better treat addictions and drug overdose, announced that members of the company’s senior management team will participate in the 12th Jefferies London Healthcare Conference virtually on Thursday, November 18 and Friday, November 19.

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended September 30, 2021.

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended September 30, 2021.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the quarter ended September 30, 2021.